Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_wilson_lower_bound float32
[ 4 ]	629	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparat...	null	Schizophrenia Schizoaffective Disorder	Lurasidone Schizophrenia Latuda	null	2	arm 1: Lurasidone arm 2: Risperidone	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 40 - 120mg per day intervention 2: Risperidone	intervention 1: Lurasidone HCl intervention 2: Risperidone	73	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Cerritos \| California \| United States \| -118.06479 \| 33.85835 Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Garden Gro...	621	NCT00641745	1COMPLETED	2010-07-01	2008-03-01	Sumitomo Pharma America, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	41	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	The purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm. Blood pressure measured in the aorta, a large blood vessel carrying blood away from the heart, may be a better measure of the harmful effects of high blood ...	Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study) is a prospective, open-label, comparative, randomized control trial that evaluated brachial and central hemodynamic profiles in patients taking atenolol or controlled-release carvedilol.	Hypertension		null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks intervention 2: Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks	intervention 1: Carvedilol CR intervention 2: Atenolol	1	Gainesville \| Florida \| United States \| -82.32483 \| 29.65163	41	NCT00669279	1COMPLETED	2010-07-01	2008-04-01	University of Florida	7OTHER	false	false	false	null	0
[ 4 ]	278	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Asthma affects about 4 million children in the United States and is a leading cause of hospitalizations and school absenteeism. Continuous wheezing in very young children may develop into asthma. Low doses of inhaled corticosteroids (ICS) are commonly prescribed to treat children with particularly bad wheezing episodes...	Childhood asthma can be caused by many factors, including allergens, cigarette smoke, air pollution, or infections. Symptoms include wheezing, shortness of breath, chest tightness, and coughing. Wheezing illnesses are common during the first several years of life, and continuous wheezing, or recurrent intermittent whee...	Asthma		null	2	arm 1: Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days. arm 2: Participants will receive 1 mg of I...	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses. intervention 2: Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnes...	intervention 1: Budesonide intervention 2: Placebo Budesonide	5	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 San Diego \| California \| United States \| -117.16472 \| 32.71571 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 Madison \| Wisconsin \| United States \| -89.40123 \| 43.07305	278	NCT00675584	1COMPLETED	2010-07-01	2008-08-01	Milton S. Hershey Medical Center	7OTHER	false	false	false	null	0
[ 0 ]	2	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	0ALL	false	Arthritis of the base of the thumb is a common debilitating problem. It is believed that laxity (loosening) of the joint leads to worsening arthritis in this joint. This can be treated by securing the joint surgically or symptoms can be treated with hand therapy and/or injection of corticosteroids. Recently prolotherap...	Dextrose prolotherapy has been shown to decrease anterior cruciate ligament (ACL) laxity and decrease knee joint pain. Similar to ACL laxity leading to knee osteoarthritis, laxity of the "beak" ligament can lead to worsening thumb CMC osteoarthritis. We hypothesize that dextrose intra-articular prolotherapy will have s...	Thumb Carpometacarpal Joint Osteoarthritis	thumb carpo metacarpal joint osteoarthritis prolotherapy intra articular steroid hand therapy	null	2	arm 1: Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint. arm 2: Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Dextrose diluted with sterile water. intervention 2: CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subject...	intervention 1: Prolotherapy (10% dextrose solution) intervention 2: Betamethasone	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	2	NCT00685880	6TERMINATED	2010-07-01	2008-05-01	Mayo Clinic	7OTHER	false	false	false	null	0
[ 3 ]	318	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with at least 1 DMARD in a 12-week therapy.	null	Arthritis, Rheumatoid	Phase 2 monotherapy in Japan	null	6	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None	[ 2, 0, 0, 0, 0, 0 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: Placebo BID, 3 blinded tablets administered BID for 12 weeks intervention 2: 10mg BID, 3 blinded tablets administered BID for 12 weeks intervention 3: 15mg BID, 3 blinded tablets administered BID for 12 weeks intervention 4: 1mg BID, 3 blinded tablets administered BID for 12 weeks intervention 5: 3mg BI...	intervention 1: Placebo intervention 2: CP-690,550 intervention 3: CP-690,550 intervention 4: CP-690,550 intervention 5: CP-690,550 intervention 6: CP-690,550	40	Nagoya \| Aichi-ken \| Japan \| 136.90641 \| 35.18147 Chiba \| Chiba \| Japan \| 140.11667 \| 35.6 Narashino \| Chiba \| Japan \| 140.04152 \| 35.68184 Yotukaidou \| Chiba \| Japan \| N/A \| N/A Fukuoka \| Fukuoka \| Japan \| 130.41667 \| 33.6 Iiduka \| Fukuoka \| Japan \| N/A \| N/A Kitakyushu \| Fukuoka \| Japan \| 130.85034 \| 33.85181 Kurume ...	317	NCT00687193	1COMPLETED	2010-07-01	2009-03-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 4 ]	515	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	null	A study designed to see if the study drug will increase blood levels of vitamin D, bone mineral density (BMD), improve biochemical markers of bone turnover, and reduce the number of falls as compared to women receiving standard care for osteoporosis.	null	Osteoporosis		null	2	arm 1: alendronate sodium (+) cholecalciferol arm 2: Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.	[ 0, 5 ]	3	[ 0, 7, 10 ]	intervention 1: FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52). intervention 2: Calcium supplied locally by the investigator (containing 500 mg calcium ...	intervention 1: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol) intervention 2: Calcium Supplement 500 mg intervention 3: Referred-Care Model	0	null	512	NCT00692913	1COMPLETED	2010-07-01	2008-06-01	Organon and Co	4INDUSTRY	false	false	false	null	0
[ 4 ]	351	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous methoxy polyethylene glycolepoetin beta (Mircera) for the maintenance of hemoglobin levels in hemodialysis participants with chronic renal anemia. Participants currently receiving intravenous epoetin al...	null	Anemia		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.	intervention 1: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)	60	Acireale \| N/A \| Italy \| 15.16577 \| 37.60886 Ancona \| N/A \| Italy \| 13.5103 \| 43.60717 Anzio \| N/A \| Italy \| 12.62157 \| 41.45263 Arenzano \| N/A \| Italy \| 8.68315 \| 44.40521 Ascoli Piceno \| N/A \| Italy \| 13.57395 \| 42.85351 Avellino \| N/A \| Italy \| 14.79103 \| 40.91494 Benevento \| N/A \| Italy \| 14.77816 \| 41.1307 Bollate...	351	NCT00699348	1COMPLETED	2010-07-01	2008-07-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	-0
[ 5 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Benzodiazepines (BZDs) have been reported to cause negative impacts on motor as well as cognitive functions, which in turn could result in lethal incidents including falls especially in the elderly. This notwithstanding, few trials have evaluated a feasibility and benefits of discontinuing BZD-derivative hypnotics in a...	Benzodiazepines (BZDs) have been reported to cause negative impacts on motor as well as cognitive functions, which in turn could result in lethal incidents including falls especially in the elderly. This notwithstanding, few trials have evaluated a feasibility and benefits of discontinuing BZD-derivative hypnotics in a...	Adverse Effects	aged benzodiazepines hypnotics cognition posture	null	1	arm 1: The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam. All psychotropic agents other than the BZD-derivative hypnotics will be kept con...	intervention 1: Drug: Benzodiazepine (listed out below)	1	Hannou \| Saitama \| Japan \| N/A \| N/A	30	NCT00707915	1COMPLETED	2010-07-01	2008-01-01	Minamihanno Hospital	7OTHER	false	false	false	null	0
[ 3 ]	25	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The primary objective is to evaluate if the application of TachoSil® on a colorectal anastomosis is feasible and safe. The secondary objective is to establish and describe optimal application methods to be used for educational purposes in future trials.	null	Colorectal Anastomosis	Colorectal Anastomosis Colorectal Resection Tachosil	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin. Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, a...	intervention 1: TachoSil®	3	Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Utrecht \| N/A \| Netherlands \| 5.12222 \| 52.09083 Dartford \| Kent \| United Kingdom \| 0.21423 \| 51.44657	25	NCT00713661	1COMPLETED	2010-07-01	2008-06-01	Nycomed	4INDUSTRY	false	false	false	null	0
[ 4 ]	121	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.	null	Fungal Infection		null	2	arm 1: caspofungin acetate (MK0991) arm 2: Micafungin sodium	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 wee...	intervention 1: caspofungin acetate intervention 2: Comparator: Micafungin sodium	0	null	120	NCT00717860	1COMPLETED	2010-07-01	2008-08-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 5 ]	45	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Many people with HIV fail to regain normal CD4 counts despite effectively suppressing HIV replication with medications. Blocking the "co-receptor" for HIV might decrease inflammation of the immune system, potentially providing an immune benefit. The goal of the current trial is to determine whether adding maraviroc, a ...	Our primary hypothesis is that CCR5 inhibitors may have protective immunomodulatory effects independent of their impact on HIV replication. Specifically, we predict that maraviroc will reduce the persistent T cell activation that prevents normal immune reconstitution during HAART-mediated viral suppression. This hypoth...	HIV Infection	HIV infection T cell activation Antiretroviral Therapy CCR5 Maraviroc	null	2	arm 1: Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens). arm 2: Placebo (dose based on current medications in regime...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens. intervention 2: Dose based on current medications in regimen: 150mg orally (PO) twice...	intervention 1: Placebo intervention 2: Maraviroc	4	San Francisco \| California \| United States \| -122.41942 \| 37.77493 Stanford \| California \| United States \| -122.16608 \| 37.42411 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	45	NCT00735072	1COMPLETED	2010-07-01	2008-09-01	University of California, San Francisco	7OTHER	false	false	false	null	0
[ 5 ]	90	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the antiviral activity and safety of tenofovir disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living in the United States) with chronic hepatitis B infection. All participants will receive active treatment with TDF for 48 weeks.	Efficacy of TDF will be evaluated for reductions in serum HBV DNA, changes in liver enzymes, and the generation of antibody to the virus. Safety will be assessed by evaluating adverse events, laboratory abnormalities, and the development of drug resistance mutations.	Chronic Hepatitis B	Hepatitis B Hepatitis Tenofovir disoproxil fumarate Tenofovir DF Asian-American	null	1	arm 1: 300-mg tablet (marketed formulation) taken orally once daily	[ 0 ]	1	[ 0 ]	intervention 1: 300-mg tablet (marketed formulation) taken orally once daily	intervention 1: Tenofovir disoproxil fumarate	21	Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Hacienda Heights \| California \| United States \| -117.96868 \| 33.99307 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Monterey Park \| California \| United States \| -118.12285 \| 34.06251 Mountain View \| California \| United States \| -122...	90	NCT00736190	1COMPLETED	2010-07-01	2008-08-01	Gilead Sciences	4INDUSTRY	false	false	false	null	0
[ 5 ]	231	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus	null	Hypertension Type 2 Diabetes Mellitus	nebivolol Bystolic ™ Hypertension Diabetes	null	3	arm 1: * Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration * Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration * Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration * Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration *...	[ 0, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: * Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration * Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration * Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration * Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral adminis...	intervention 1: Nebivolol intervention 2: Metoprolol ER intervention 3: HCTZ	65	Athens \| Alabama \| United States \| -86.97219 \| 34.80243 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Bell Gardens \| California \| United States \| -118.15146 \| 33.96529 Buena Park \| California \| United States \| -117.99812 \| 33.86751 Chino \| California \| United States \| -117.68894 \| 34.01223 Fremont \| Califo...	230	NCT00744237	1COMPLETED	2010-07-01	2008-08-01	Forest Laboratories	4INDUSTRY	false	false	false	null	0
[ 0 ]	11	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Almost 80% of panic disorder patients report difficulty sleeping. Sleep disturbances in turn may exacerbate underlying anxiety/panic attacks. Moreover, individuals with insomnia (sleep disturbance) are at higher risk of developing a new anxiety disorder. Therefore it is expected that improving sleep quality with medica...	null	Panic Disorder Insomnia	insomnia sleep difficulty panic disorder nocturnal panic attacks anxiety	null	2	arm 1: Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram. arm 2: Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Placebo and Escitalopram (5 to 40 mg) intervention 2: Ramelteon 8 mg and Escitalopram (5-40 mg)	intervention 1: Placebo and Escitalopram intervention 2: Ramelteon and Escitalopram	1	Hershey \| Pennsylvania \| United States \| -76.65025 \| 40.28592	11	NCT00746239	6TERMINATED	2010-07-01	2008-08-01	Milton S. Hershey Medical Center	7OTHER	false	false	false	null	0
[ 5 ]	40	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Methamphetamine dependence is a serious public health problem with no pharmacologic treatments currently available. Relapse rates are high in this population. Exposure to cues previously associated with methamphetamine use may induce profound craving in abstinent individuals. Chronic methamphetamine abuse is associated...	null	Methamphetamine Dependence	Methamphetamine Modafinil Addiction Craving Cognitive	null	2	arm 1: Modafinil 400 mg daily arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 400 mg daily for four weeks intervention 2: Placebo 2 tablets daily for 4 weeks	intervention 1: Modafinil intervention 2: Placebo	1	Pickens \| South Carolina \| United States \| -82.70736 \| 34.88345	40	NCT00751023	1COMPLETED	2010-07-01	2009-02-01	Medical University of South Carolina	7OTHER	false	false	false	null	0
[ 3 ]	92	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The purpose of this study is to determine if the traditional Chinese herbal compound (Huo-Luo-Xiao-Ling Dan, or HLXL) is effective in treating OA of the knee in addition to participants current OA of the knee treatment(s) and also to determine the best dosage of HLXL that is safe and well tolerated.	The specific aims of this project are: 1. To determine whether HLXL improves pain and/or function in patients with OA of the knee who continue to have symptoms despite receiving standard analgesic and/or anti-inflammatory treatment, 2. To identify an optimal dosage of HLXL, among two dosages, as determined by pain rel...	Osteoarthritis of the Knee	OA	null	2	arm 1: Active herb Huo-Luo-Xiao-Ling (HLXL) The subjects in the HLXL group received the medium dose of HLXL (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/day) for the subsequent 6 weeks. arm 2: Place...	[ 1, 2 ]	1	[ 0 ]	intervention 1: Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.	intervention 1: HLXL	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	92	NCT00755326	1COMPLETED	2010-07-01	2007-04-01	University of Maryland, Baltimore	7OTHER	false	false	false	null	0
[ 4 ]	540	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their hepatitis C virus (HCV). The study is designed to look at the relative benefits of 24 or 48...	null	Hepatitis C	Genotype 1	null	4	arm 1: Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group arm 2: Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + R...	[ 0, 0, 0, 0 ]	3	[ 0, 0, 2 ]	intervention 1: 750 mg every 8 hours (q8h) for 12 weeks intervention 2: 1000 - 1200 mg/day based on body weight for either 24 or 48 weeks intervention 3: 180 mcg/week for either 24 or 48 weeks	intervention 1: telaprevir intervention 2: ribavirin intervention 3: peginterferon alfa-2a	82	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Fresno \| California \| United States \| -119.77237 \| 36.74773 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Los Angeles \| Califor...	540	NCT00758043	1COMPLETED	2010-07-01	2008-10-01	Vertex Pharmaceuticals Incorporated	4INDUSTRY	false	false	false	null	0
[ 4 ]	217	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	false	The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level of sexual distress when taking SH T00658ID compared to Microgynon, the usual OC prescribed...	null	Contraception Libido	Oral contraceptive Sexual dysfunction Libido	null	2	arm 1: Daily oral administration of one capsule BAY86-5027 \[estradiol valerate (EV) / dienogest (DNG)\] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles. arm 2: Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placeb...	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, plac...	intervention 1: EV/DNG (Qlaira, BAY86-5027, SH T00658ID) intervention 2: Microgynon intervention 3: Placebo	32	Ashfield \| New South Wales \| Australia \| 151.12274 \| -33.88834 Sydney \| New South Wales \| Australia \| 151.20732 \| -33.86785 Adelaide \| South Australia \| Australia \| 138.59863 \| -34.92866 Prahran \| Victoria \| Australia \| 144.99318 \| -37.85114 Nedlands \| Western Australia \| Australia \| 115.8073 \| -31.98184 Subiaco \| West...	213	NCT00764881	1COMPLETED	2010-07-01	2009-01-01	Bayer	4INDUSTRY	false	false	false	null	0
[ 5 ]	12	RANDOMIZED	CROSSOVER	1PREVENTION	4QUADRUPLE	false	0ALL	true	Coarctation of the aorta (CoA) accounts for approximately 8% of all congenital heart problems. Patients with CoA are well known to have an increased rates of early heart disease, high blood pressure, heart failure and stroke. Abnormal arterial function (dilation and constriction of the blood vessels) has been observed ...	The study design is a randomized double-blind cross over clinical trial. Patients who meet inclusion criteria and no exclusion criteria will be enrolled. They will undergo a baseline cardiovascular assessment including echocardiography, magnetic resonance imaging or magnetic resonance angiography (MRI/MRA), serum blood...	Coarctation of the Aorta	Coarctation of the aorta cross over design atorvastatin endothelial function	null	2	arm 1: Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy. arm 2: See above. Patients will be randomized to atorvastatin ...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12) intervention 2: atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Tot...	intervention 1: atorvastatin intervention 2: Sugar pill	1	San Francisco \| California \| United States \| -122.41942 \| 37.77493	24	NCT00767572	6TERMINATED	2010-07-01	2008-08-01	University of California, San Francisco	7OTHER	false	false	false	null	0
[ 5 ]	11	RANDOMIZED	PARALLEL	1PREVENTION	0NONE	false	0ALL	false	To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.	We will evaluate the therapeutic efficacy of administering Thymoglobulin® induction pre-transplantation in renal allograft recipients. Patients receiving pre-transplant Thymoglobulin will be evaluated for acute rejection (Banff '97 criteria), survival, and safety at 6 months. Overall the use of Thymoglobulin induction ...	Renal Transplant Rejection Transplants and Implants		null	2	arm 1: Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF arm 2: Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF intervention 2: Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper +...	intervention 1: Thymoglobulin intervention 2: Thymoglobulin	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	11	NCT00771745	1COMPLETED	2010-07-01	2008-09-01	University of Cincinnati	7OTHER	false	false	false	null	0
[ 4 ]	32	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.	null	Hepatitis C		null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: 750 mg every 8 hours for 12 weeks intervention 2: 600 - 1000 mg/day based on body weight for 24 weeks intervention 3: 1.5 mcg/kg/week for 24 weeks	intervention 1: MP-424 intervention 2: Ribavirin intervention 3: Peginterferon Alfa-2b	1	Kawasaki \| Takatsu-ku \| Japan \| 139.71722 \| 35.52056	32	NCT00781274	1COMPLETED	2010-07-01	2008-12-01	Mitsubishi Tanabe Pharma Corporation	4INDUSTRY	false	false	false	null	0
[ 5 ]	181	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to compare two different treatment protocols for treating nausea and vomiting in patients who have undergone bone marrow transplant. Patients will be assigned to one of two treatment groups. The first group will recieve ondansetron (Zofran) tablets combined with a medicine called dexametha...	This will be a single center, comparative, randomized, double-blind, phase III trial designed to evaluate the efficacy of the NK-1 antagonist, aprepitant (MK-869), in combination with ondansetron and dexamethasone in the prevention of acute and delayed nausea and vomiting compared to ondansetron and dexamethasone in pa...	Nausea Vomiting	Bone Marrow Transplant Nausea Vomiting NK-1 antagonist	null	2	arm 1: Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. arm 2: Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD o...	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start...	intervention 1: Standard PO (Zofran + Dexamethason) intervention 2: Aprepitant (MK-869) + Standard PO	0	null	179	NCT00781768	1COMPLETED	2010-07-01	2003-08-01	Loyola University	7OTHER	false	false	false	null	0
[ 3 ]	263	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	false	The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.	null	Macular Edema	diabetic retinopathy cystoid macular edema;	null	2	arm 1: One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter. arm 2: One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereaft...	[ 0, 2 ]	3	[ 0, 10, 0 ]	intervention 1: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery. intervention 2: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery intervention 3: One drop in the stu...	intervention 1: Nepafenac ophthalmic suspension, 0.1% (NEVANAC) intervention 2: Nepafenac ophthalmic suspension vehicle intervention 3: Prednisolone acetate ophthalmic suspension (OMNIPRED)	0	null	253	NCT00782717	1COMPLETED	2010-07-01	2008-11-01	Alcon Research	4INDUSTRY	false	false	false	null	0
[ 5 ]	14	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.	null	Cystic Fibrosis Allergic Bronchopulmonary Aspergillosis	Cystic Fibrosis Allergic Bronchopulmonary Aspergillosis omalizumab oral corticosteroid use anti-immunoglobulin E	null	2	arm 1: Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to ...	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Omalizumab subcutaneous injections of 600 mg daily. intervention 2: Placebo subcutaneous injections blinded to match experimental arm dosing regimen. intervention 3: Itraconazole twice daily with a maximum daily dose of 400 mg.	intervention 1: Omalizumab intervention 2: Placebo intervention 3: Itraconazole	10	Leuven \| N/A \| Belgium \| 4.70093 \| 50.87959 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Bonn \| N/A \| Germany \| 7.09549 \| 50.73438 Munich \| N/A \| Germany \| 11.57549 \| 48.13743 Milan \| N/A \| Italy \| 9.18951 \| 45.46427 Rome \| N/A \| Italy \| 12.51133 \| 41.89193 Nijmegen \| N/A \| Netherlands \| 5.85278 \| 51.8425 Utrecht \| N/A...	21	NCT00787917	6TERMINATED	2010-07-01	2008-11-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	430	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	1FEMALE	false	The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.	null	Acute Pain Following a Total Abdominal Hysterectomy		null	3	arm 1: etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days. arm 2: etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days. arm 3: Placebo- 3 tablets once daily	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 120 mg of etoricoxib (MK0663) for a total of 5 days intervention 2: Placebo tablets once daily on Days 1-5. Total treatment is 5 days. intervention 3: 90 mg of etoricoxib (MK0663) for a total of 5 days	intervention 1: etoricoxib (MK0663) 120 mg intervention 2: Comparator: Placebo intervention 3: etoricoxib (MK0663) 90 mg	0	null	430	NCT00788710	1COMPLETED	2010-07-01	2008-10-01	Organon and Co	4INDUSTRY	false	false	false	null	0
[ 4 ]	488	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.	null	Schizophrenia	Schizophrenia SM-13496 Latuda Lurasidone	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Lurasidone 80 mg tablets intervention 2: Lurasidone 4 40 mg tablets intervention 3: Quetiapine XR 600mg intervention 4: Matching Placebo to Lurasidone or Quetiapine	intervention 1: Lurasidone intervention 2: Lurasidone intervention 3: Quetiapine XR intervention 4: Placebo	65	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Cerritos \| California \| United States \| -118.06479 \| 33.85835 Cerritos \| California \| United States \| -118.06479 \| 33.85835 Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Escondid...	486	NCT00790192	1COMPLETED	2010-07-01	2008-10-01	Sumitomo Pharma America, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	676	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).	null	Obesity	Obesity	null	3	arm 1: Placebo arm 2: 7.5 mg phentermine and 46 mg topiramate arm 3: 15 mg phentermine and 92 mg topiramate	[ 2, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 7.5 mg phentermine and 46 mg topiramate intervention 2: placebo intervention 3: 15 mg phentermine and 92 mg topiramate	intervention 1: VI-0521 intervention 2: Placebo intervention 3: VI-0521	0	null	675	NCT00796367	1COMPLETED	2010-07-01	2008-12-01	VIVUS LLC	4INDUSTRY	false	false	false	null	0
[ 3 ]	850	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.	A comparison of the Fixed dose arm (OPC-31712, 0.15 mg) verses placebo was included as a general secondary efficacy variable and results for this dose group comparison are included under each of the Outcome Measures.	Major Depressive Disorder	OPC-34712, Major Depressive Disorder, Adjunctive Treatment	null	2	arm 1: OPC-34712 + ADT arm 2: Placebo + ADT	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks intervention 2: Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks intervention 3: Tablets, 10 - 225 mgs, dose once daily, 14 weeks	intervention 1: OPC-34712 intervention 2: Placebo intervention 3: ADT	50	Arcadia \| California \| United States \| -118.03534 \| 34.13973 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Escondido \| California \| United States \| -117.08642 \| 33.11921 Garden Grove \| California \| United States \| -117.94145 \| 33.77391 National City \| California \| United States \| -117.0992 \| 32.678...	429	NCT00797966	1COMPLETED	2010-07-01	2009-05-01	Otsuka Pharmaceutical Development & Commercialization, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	326	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular h...	null	Vitreomacular Adhesion		null	2	arm 1: 125µg of ocriplasmin intravitreal injection arm 2: Intravitreal injection of placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 125µg of ocriplasmin intravitreal injection intervention 2: Intravitreal injection placebo.	intervention 1: Ocriplasmin 125µg intervention 2: Placebo	48	Campbell \| California \| United States \| -121.94996 \| 37.28717 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Santa Barbara \| California \| United States \| -119.69819 \| 34.42083 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Pensacola \| Florida \| United States \| -87.21691 \| 30.42131 Paducah \| ...	326	NCT00798317	1COMPLETED	2010-07-01	2008-12-01	ThromboGenics	4INDUSTRY	false	false	false	null	0
[ 5 ]	75	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The primary objective of the study is to assess the benefice of Vyvanse on the factors that cause impairments in driving behavior in individuals with ADHD using a driving simulation aimed at examining the factors that cause impairments in driving behavior in individuals with ADHD such as driving speed, collision risk, ...	null	Attention Deficit/Hyperactivity Disorder(ADHD)	ADHD young adults driving Vyvanse lisdexamfetamine	null	2	arm 1: Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily. arm 2: Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Vyvanse 30, 50, or 70 mg daily intervention 2: Placebo 30, 50, 70 mg daily	intervention 1: Vyvanse intervention 2: Placebo	1	Cambridge \| Massachusetts \| United States \| -71.10561 \| 42.3751	69	NCT00801229	1COMPLETED	2010-07-01	2008-12-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0
[ 4 ]	129	RANDOMIZED	SINGLE_GROUP	0TREATMENT	1SINGLE	false	0ALL	false	To compare the safety and tolerability of sodium oxybate given as a combination of an oral solution and oral tablets for 4 weeks in subjects with fibromyalgia (FM).	null	Fibromyalgia		null	4	arm 1: Sodium Oxybate Oral Solution (4.5 grams) arm 2: Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams) arm 3: Sodium Oxybate Oral Solution (6 grams) arm 4: Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 4.5 grams per night taken in two equally divided doses intervention 2: 4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night intervention 3: 6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night interventio...	intervention 1: Sodium Oxybate intervention 2: Sodium Oxybate & 6 Tablets intervention 3: Sodium Oxybate & 8 Tablets intervention 4: Sodium Oxybate Oral Solution (6 grams)	32	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Fair Oaks \| California \| United States \| -121.27217 \| 38.64463 Northridge \| Californ...	129	NCT00803023	1COMPLETED	2010-07-01	2010-03-01	Jazz Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	39	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response to previous treatment with 5 mg/kg of REMICADE every 8 weeks.	null	Crohn's Disease	Infliximab REMICADE Crohn's disease	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: (1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infus...	intervention 1: TA-650	4	Hokkaido \| N/A \| Japan \| N/A \| N/A Kansai \| N/A \| Japan \| N/A \| N/A Kanto \| N/A \| Japan \| N/A \| N/A Kyushu \| N/A \| Japan \| N/A \| N/A	129	NCT00805766	1COMPLETED	2010-07-01	2008-12-01	Mitsubishi Tanabe Pharma Corporation	4INDUSTRY	false	false	false	null	0
[ 0 ]	88	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	1FEMALE	false	To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three...	null	Genital Herpes	herpes simplex virus acyclovir HSV shedding women Africa	null	2	arm 1: None arm 2: None	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 400mg taken orally three times daily for 5 days intervention 2: matching placebo taken orally three times daily for 5 days.	intervention 1: acyclovir intervention 2: matching placebo	2	Johannesburg \| N/A \| South Africa \| 28.04363 \| -26.20227 Lusaka \| N/A \| Zambia \| 28.28713 \| -15.40669	88	NCT00808405	1COMPLETED	2010-07-01	2009-01-01	University of Washington	7OTHER	false	false	false	null	0
[ 3 ]	55	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to determine whether the treatment of locally advanced esophageal squamous cell carcinoma (ESCC)with cetuximab in combination with paclitaxel, cisplatin and radiation improve clinical outcomes.	Esophageal cancer is the sixth leading cause of cancer death worldwide. Over the past 2 decades, well-designed clinical trials have documented the clinical benefits of combination of chemotherapy and radiation for localized esophageal cancer, either as primary therapy or in neoadjuvant setting. Paclitaxel, a radiatio...	Esophageal Cancer	Therapeutic Drug Therapy, combination Radiotherapy	null	1	arm 1: Cetuximab, injection, loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m\^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m\^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction dai...	[ 0 ]	4	[ 0, 0, 0, 4 ]	intervention 1: Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8) intervention 2: Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8) intervention 3: Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-...	intervention 1: cetuximab (Erbitux) intervention 2: Paclitaxel intervention 3: Cisplatin intervention 4: Radiation	1	Jinan \| Shandong \| China \| 116.99722 \| 36.66833	55	NCT00815308	1COMPLETED	2010-07-01	2009-01-01	Shandong Cancer Hospital and Institute	7OTHER	false	false	false	null	0
[ 3 ]	59	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	false	The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.	null	Scar Prevention Scar Reduction	AZX100 Patient and Observer Scar Assessment Scale POSAS Visual Analog Scale VAS Keloid Scarring Scar reduction Scar prevention	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 2, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery. intervention 2: Subjects were administered AZX100 10 mg per lin...	intervention 1: AZX100 Drug Product intervention 2: AZX100 Drug Product intervention 3: Placebo	2	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Austin \| Texas \| United States \| -97.74306 \| 30.26715	59	NCT00825916	1COMPLETED	2010-07-01	2009-03-01	Capstone Therapeutics	4INDUSTRY	false	false	false	null	0
[ 0 ]	40	RANDOMIZED	PARALLEL	4SUPPORTIVE_CARE	1SINGLE	true	0ALL	false	The purpose of this study is to determine if there is a difference on the penetration of betadine 5% when using lidocaine 2% jelly versus topical tetracaine 0.5% in topical cataract surgery. This will be assessed comparing bacterial colony count and species by taking swabs from the eye surface before and after the topi...	The purpose of this research study is to show that using Lidocaine2% jelly before surgery as an anesthetic (keep you from feeling touch or pain) for cataract surgery does not block the antiseptic (cleans and kills germs) effect of Betadine5%.	Cataracts		null	2	arm 1: Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered arm 2: Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: betadine 5% intervention 2: Betadine 5%	intervention 1: tetracaine 0.5% intervention 2: Lidocaine 2% Jelly	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	40	NCT00827073	1COMPLETED	2010-07-01	2008-11-01	Hermann Eye Center	7OTHER	false	false	false	null	0
[ 3 ]	10	NON_RANDOMIZED	SINGLE_GROUP	4SUPPORTIVE_CARE	0NONE	false	0ALL	true	The major purpose of this study is to determine if a new drug called pazopanib decreases lymphedema in subjects previously treated for cancer. Lymphedema, or swelling of the arm, is a result of damage to the lymphatic vessels in the arm during surgery and/or radiation. The damaged vessels can not adequately drain fluid...	Pazopanib inhibits the growth of blood vessels in tumors by inhibiting a protein called vascular endothelial growth factor (commonly called VEGF). Pazopanib is not currently approved by the US Food and Drug Administration (FDA) and therefore considered an experimental medication. High levels of VEGF cause blood vessel...	Lymphedema		null	1	arm 1: Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)	[ 0 ]	1	[ 0 ]	intervention 1: Pazopanib will be administered at a starting dose of 800 mg orally once each day.	intervention 1: Pazopanib	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	10	NCT00827372	1COMPLETED	2010-07-01	2009-01-01	Kathy Miller	7OTHER	false	false	false	null	0
[ 4 ]	42	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	2MALE	false	The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on the same symptoms. The advancement/worsening of prostate cancer may be associated with LUTS a...	null	Prostate Cancer		null	2	arm 1: Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL) arm 2: Goserelin (3.6 mg) + bicalutamide (50 mg)	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on D...	intervention 1: Degarelix intervention 2: Goserelin intervention 3: Bicalutamide	33	Bamberg \| N/A \| Germany \| 10.90067 \| 49.89873 Borken \| N/A \| Germany \| 6.85774 \| 51.84382 Cologne \| N/A \| Germany \| 6.95 \| 50.93333 Dresden \| N/A \| Germany \| 13.73832 \| 51.05089 Fürth \| N/A \| Germany \| 10.98856 \| 49.47593 Hamburg \| N/A \| Germany \| 9.99302 \| 53.55073 Leipzig \| N/A \| Germany \| 12.37129 \| 51.33962 Offenba...	40	NCT00831233	6TERMINATED	2010-07-01	2009-04-01	Ferring Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	49	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study is the extension of the CLARINET study \[NCT00396877 -EFC5314\] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt. The primary objective was to assess the safety up to 18 months of age of the extended use of Clopidogrel 0.2 mg/kg/day in patient...	Patients remained in the treatment group to which they were originally allocated for the CLARINET study and continued blindly their treatment (0.2 mg/kg/day of clopidogrel or placebo) up to the occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of...	Heart Defects, Congenital	cyanotic congenital heart disease shunt palliation thrombosis clopidogrel	null	2	arm 1: 0.2 mL/kg/day matching placebo solution once daily. arm 2: 0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: Form: reconstituted solution using Clopidogrel powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight intervention 2: Form: reconstituted solution using matching placebo powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight	intervention 1: Clopidogrel intervention 2: placebo	15	Bridgewater \| New Jersey \| United States \| -74.64815 \| 40.60079 São Paulo \| N/A \| Brazil \| -46.63611 \| -23.5475 Paris \| N/A \| France \| 2.3488 \| 48.85341 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Budapest \| N/A \| Hungary \| 19.04045 \| 47.49835 Mumbai \| N/A \| India \| 72.88261 \| 19.07283 Milan \| N/A \| Italy \| 12.59836 \|...	49	NCT00833703	1COMPLETED	2010-07-01	2009-01-01	Sanofi	4INDUSTRY	false	false	false	null	0
[ 5 ]	43	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	true	0ALL	true	Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin sensitivity in skeletal muscle, liver, and fat cells. Despite the beneficial effects of pioglitazone to improve insulin sensitivity and reduce cardiovascular disease in high risk type 2 diabetic patients, weight gain has been a ...	The thiazolidinedione (TZD) class of drugs has been shown to improve insulin sensitivity in skeletal muscle, liver, and adipocytes and to have anti-inflammatory and cardioprotective effects. The beta cell function, measured by the insulin secretion/insulin resistance index during the OGTT, improves significantly. In th...	Type 2 Diabetes Healthy Impaired Glucose Tolerance	Type 2 diabetes pathogenesis, thiazolidinediones impaired glucose tolerance Incretins Insulin secretion	null	3	arm 1: Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm arm 2: Exenatide: 15 subjects will be randomized to receive Exenatide arm 3: Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide	[ 1, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months intervention 2: Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months intervention 3: Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twic...	intervention 1: Pioglitazone intervention 2: Exenatide intervention 3: Pioglitazone and Exenatide	1	San Antonio \| Texas \| United States \| -98.49363 \| 29.42412	42	NCT00845182	1COMPLETED	2010-07-01	2007-06-01	The University of Texas Health Science Center at San Antonio	7OTHER	false	false	false	null	0
[ 4 ]	1,711	RANDOMIZED	FACTORIAL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.	According to the World Health Organization (WHO), hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. As the population ages, the prevalence of hyperte...	Hypertension	Hypertensive Blood Pressure, High Vascular Disease Cardiovascular Disease Drug Therapy	null	11	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None arm 8: None arm 9: None arm 10: None arm 11: None	[ 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0 ]	11	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks intervention 2: Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks intervention 3: Azilsartan 40 mg and chlorthalidone 12.5 mg combin...	intervention 1: Azilsartan medoxomil and chlorthalidone intervention 2: Azilsartan medoxomil and chlorthalidone intervention 3: Azilsartan medoxomil and chlorthalidone intervention 4: Azilsartan medoxomil and chlorthalidone intervention 5: Azilsartan medoxomil and chlorthalidone intervention 6: Azilsartan medoxomil and...	99	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Columbiana \| Alabama \| United States \| -86.60721 \| 33.17817 Tuscaloosa \| Alabama \| United States \| -87.56917 \| 33.20984 Chandler \| Arizona \| United States \| -111.84125 \| 33.30616 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Scottsdale \| Arizona \| ...	1,712	NCT00847626	1COMPLETED	2010-07-01	2009-01-01	Takeda	4INDUSTRY	false	false	false	null	0
[ 0 ]	21	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.	null	Congenital Heart Disease	Cardiopulmonary Bypass ACE inhibitor Pediatrics	null	2	arm 1: Patients already on an ACE inhibitor will continue it until the day of surgery arm 2: Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery	[ 0, 0 ]	2	[ 0, 10 ]	intervention 1: Patients randomized to this group will continue their current dose of ACE inhibitors until surgery intervention 2: Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery	intervention 1: Angiotensin Converting Enzyme Inhibitor intervention 2: No ACE Inhibitor	1	Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	20	NCT00848250	1COMPLETED	2010-07-01	2008-09-01	Vanderbilt University Medical Center	7OTHER	false	false	false	null	0
[ 4 ]	606	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	2MALE	false	Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both ED and signs and symptoms of BPH.	null	Erectile Dysfunction Benign Prostatic Hyperplasia	Erectile Dysfunction Benign Prostatic Hyperplasia	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: tablet once daily by mouth for 12 weeks. intervention 2: Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.	intervention 1: Tadalafil intervention 2: Placebo	52	Anchorage \| Alaska \| United States \| -149.90028 \| 61.21806 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 La Mesa \| California \| United States \| -117.02308 \| 32.76783 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Newport Beach \| California \| United States \| -117.92895 \| 33.61891 San Diego ...	606	NCT00855582	1COMPLETED	2010-07-01	2009-03-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3 ]	16	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)	null	Choroidal Neo-Vascular Age-onset Macular Degeneration Age-related Macular Degeneration	AMD macular degeneration Everolimus Lucentis Ranibizumab Choroidal Neo-Vascular (CNV) age-onset macular degeneration Age-related Macular Degeneration (AMD)	null	3	arm 1: 5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28 arm 2: Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline) arm 3: Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)	[ 0, 1, 1 ]	2	[ 0, 0 ]	intervention 1: 5 mg oral tablet intervention 2: 0.5 mg administered by intravitreal injection	intervention 1: Everolimus intervention 2: Ranibizumab	12	Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Independence \| Missouri \| United States \| -94.41551 \| 39.09112 Bristol \| N/A \| United Kingdom \| -2.59665 \| 51.45523 Frimley \| N/A \| U...	15	NCT00857259	6TERMINATED	2010-07-01	2009-02-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 0 ]	30	NA	SINGLE_GROUP	2DIAGNOSTIC	1SINGLE	true	0ALL	false	We will test the hypothesis that a single dose of Regadenoson will produce equivalent degrees of coronary hyperemia in patients of widely different body size. This will be a prospective, open-label, comparative trial using MRI to measure myocardial perfusion reserve (ratio of myocardial blood flow with vasodilator to m...	Introduction: Regadenoson (Lexiscan) is currently recommended for use as a targeted vasodilator in myocardial perfusion studies and is available as a single, fixed dose for all patients. Here we propose to compare the hyperemic response measured with MRI in subjects with a wide range of BMI 18-40. MRI is an ideal test...	Obesity Endothelial Dysfunction Decreased Vascular Flow	adenosine regadenoson adenosine receptor subtypes	null	1	arm 1: Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequential...	[ 0 ]	2	[ 0, 0 ]	intervention 1: Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes). intervention 2: Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.	intervention 1: Adenosine intervention 2: Regadenoson	1	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	30	NCT00859833	1COMPLETED	2010-07-01	2009-02-01	University of Utah	7OTHER	false	false	false	null	0
[ 2 ]	28	NON_RANDOMIZED	SINGLE_GROUP	null	0NONE	true	0ALL	true	The purpose of this study is to determine the safety and effects of etravirine, an HIV antiretroviral medication, on vascular function.	We hypothesize that in HIV-uninfected subjects, etravirine 200mg twice daily for four weeks will have no effect on endothelial function. The primary objective of this study is to determine the effects of etravirine 200mg twice daily given for four weeks on endothelial function, measured as flow-mediated dilation (FMD) ...	Endothelial Function Lipids Insulin Resistance Inflammation HIV Infections	HIV Endothelial function Etravirine	null	0	null	null	1	[ 0 ]	intervention 1: Two one-hundred mg tablets orally twice daily for four weeks	intervention 1: Etravirine	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	28	NCT00871234	1COMPLETED	2010-07-01	2009-04-01	Indiana University	7OTHER	false	false	false	null	0
[ 2 ]	32	NA	SINGLE_GROUP	9OTHER	0NONE	false	0ALL	false	This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety of piperacillin-tazobactam in infants \< 61 days of age with suspected sepsis. There will be four cohorts of 8 infants each: 1. \< 32 weeks gestational age (GA) and \< 14 days postnatal age (PNA) 2. \< 32 weeks gestational age...	Procedures Prior to Receipt of First Dose of Study Drug Parental/Guardian Permission Prior to the start of any study-related procedure, a signed and dated informed consent and HIPAA authorization must be obtained and documented in the infant's medical record. Once it has been determined that the infant meets all inclu...	Sepsis	presumed sepsis	null	1	arm 1: Open label -- 6 interval doses	[ 1 ]	1	[ 0 ]	intervention 1: 6 doses intravenously at the following doses: Infants \<32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6 Infants ≥32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q6 ≥ 14 days PNA 100 mg/kg Q6	intervention 1: piperacillin-tazobactam	4	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Wichita \| Kansas \| United States \| -97.33754 \| 37.69224 Kansas City \| Missouri \| United States \| -94.57857 \| 39.09973 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	32	NCT00873327	1COMPLETED	2010-07-01	2009-10-01	Phillip Brian Smith	7OTHER	false	false	false	null	0
[ 5 ]	30	RANDOMIZED	CROSSOVER	2DIAGNOSTIC	1SINGLE	false	0ALL	true	The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.	null	Pulmonary Hypertension	Pulmonary artery systolic pressure (PASP) Pulmonary Vascular Resistance (PVR) Right Heart Catheterization Pulmonary hemodynamics	null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose. Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison. intervention 2: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by si...	intervention 1: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension) intervention 2: Dextrose	1	Elliott \| Maryland \| United States \| -75.99632 \| 38.31012	30	NCT00878878	1COMPLETED	2010-07-01	2009-03-01	GE Healthcare	4INDUSTRY	false	false	false	null	0
[ 4 ]	388	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.	null	Schizophrenia	Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) qualified PANSS assessment	null	2	arm 1: Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day) arm 2: Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 200 mg or 300 mg, oral, single dose intervention 2: 50 mg, oral, double dose	intervention 1: Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) intervention 2: Chlorpromazine	11	Hunan \| Changsha \| China \| 118.85431 \| 33.9693 Guangzhou \| Guangdong \| China \| 113.25 \| 23.11667 Baoding \| Hebei \| China \| 115.46246 \| 38.87288 Harbin \| Heilongjiang \| China \| 126.65 \| 45.75 Wuhan \| Hubei \| China \| 114.26667 \| 30.58333 Changsha \| Hunan \| China \| 112.97087 \| 28.19874 Nanjing \| Jiangsu \| China \| 118.7777...	388	NCT00882518	1COMPLETED	2010-07-01	2009-04-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 5 ]	16	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	It is possible to offer smoking cessation treatment including varenicline to patients scheduled for elective surgery. This study will evaluate whether or not this will enable some patients to quit smoking for up to 4 weeks prior to surgery and in turn, whether this may lead to reductions in post-operative complication ...	Recruitment to this study was terminated (on February 23, 2010) earlier than originally planned because recruitment was much slower than expected and therefore the study has already achieved its main objective of assessing the feasibility of conducting a larger study of similar design to investigate the efficacy of smo...	Smoking Cessation	smoking cessation varenicline elective surgery wound infections post-operative complications	null	1	arm 1: None	[ 5 ]	1	[ 0 ]	intervention 1: Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd	intervention 1: Varenicline	2	Paris \| N/A \| France \| 2.3488 \| 48.85341 Pisa \| N/A \| Italy \| 10.4036 \| 43.70853	16	NCT00889720	1COMPLETED	2010-07-01	2009-11-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 5 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to investigate the effectiveness and tolerability of riluzole in adults with Fragile X Syndrome.	Fragile X Syndrome (FXS) represents the most common inherited form of intellectual disability. FXS is more common in males and the symptoms associated with the disorder are more marked in males. FXS is associated with characteristic physical features, behaviors, and comorbidities. Those with FXS often suffer from behav...	Fragile X Syndrome		null	1	arm 1: Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.	[ 0 ]	1	[ 0 ]	intervention 1: Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.	intervention 1: Riluzole	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	6	NCT00895752	1COMPLETED	2010-07-01	2009-04-01	Indiana University	7OTHER	false	false	false	null	0
[ 3 ]	127	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics were enrolled. Screening evaluations were performed within appro...	null	Rheumatoid Arthritis	Rheumatoid arthritis	null	4	arm 1: INCB028050 4mg Once daily (QD) arm 2: INCB028050 7mg QD arm 3: INCB028050 10mg QD arm 4: Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 4 mg capsules QD intervention 2: 7 mg capsules QD intervention 3: 10 mg capsule QD intervention 4: Placebo matching INCB028050 QD	intervention 1: INCB028050 intervention 2: INCB028050 intervention 3: INCB028050 intervention 4: Placebo	49	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Paradise Valley \| Arizona \| United States \| -111.94265 \| 33.53115 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Palm Desert \| California \| United States \| -116.37697 \| 33.72255 Santa Maria \| C...	355	NCT00902486	1COMPLETED	2010-07-01	2009-05-01	Incyte Corporation	4INDUSTRY	false	false	false	null	0
[ 4 ]	23	RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Objectives: To investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic malignancies.	Chemotherapy can lower immune system function, which can cause fungal infections to occur more easily. These fungal infections are found by certain blood tests. One of these blood tests looks for a part of the fungal cell floating freely in the human blood. When certain drugs are given to patients to prevent fungal in...	Leukemia Fungal Infection	Leukemia Cancer of the blood Cancer of the bone marrow Hematologic malignancy Invasive fungal infection Voriconazole Vfend antifungal prophylaxis	null	2	arm 1: Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter. arm 2: Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter. intervention 2: 6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.	intervention 1: Voriconazole intervention 2: Voriconazole	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	21	NCT00904995	1COMPLETED	2010-07-01	2009-05-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0
[ 4 ]	213	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and exercise.	null	Type 2 Diabetes	DPP-4 inhibitors HbA1c Incretins	null	2	arm 1: Saxagliptin arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Oral tablet, once daily for 24 weeks intervention 2: Oral tablet, once daily for 24 weeks	intervention 1: Saxagliptin intervention 2: Placebo	9	Gujarat \| Ahmedabad \| India \| N/A \| N/A Karnataka \| Bangalore \| India \| N/A \| N/A Tamil Nadu \| Chennai \| India \| N/A \| N/A Tamil Nadu \| Coimbatore \| India \| N/A \| N/A Andhra Pradesh \| Hyderabad \| India \| N/A \| N/A Madhya Pradesh \| Indore \| India \| N/A \| N/A Haryāna \| Karnal \| India \| 76.98056 \| 29.61611 Kerala \| Kochi ...	213	NCT00918879	1COMPLETED	2010-07-01	2009-05-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 3, 4 ]	21	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	true	Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic kidney disease (ADPKD). Patients will be followed by volumetric magnetic resonance imaging (...	This is a 2 year, open label trial to evaluate the role of rapamycin as treatment for ADPKD. Patients will be randomized 2:1 to the rapamycin arm or to standard therapy. The dose of rapamycin will be adjusted so that patients obtain 24 trough levels of 4-6ng/ml. There will be a volumetric MRI measurement at the start a...	Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney Disease rapamycin ADPKD	null	2	arm 1: Drug: Rapamycin Other Names: sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml. arm 2: Standard of Care	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml. intervention 2: None	intervention 1: Rapamycin intervention 2: Standard of Care-Placebo	1	New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815	21	NCT00920309	6TERMINATED	2010-07-01	2009-06-01	Yale University	7OTHER	false	false	false	null	0
[ 3 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	false	2MALE	false	The purpose of the study is to determine the effect of food with various amounts of fat on the absorption of an oral testosterone undecanoate formulation.	Pharmacokinetics will be evaluated after the following types of meals: very low fat, low fat, normal diet, high fat, and fasting. Subjects will have one dose of TU administered 30 minutes after the initiation of the meal.	Male Hypogonadism	Primary hypogonadism Secondary hypogonadism	null	5	arm 1: Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state arm 2: Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with very low fat (6-10% fat). arm 3: Si...	[ 0, 0, 0, 0, 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Oral testosterone undecanoate (containing 300 mg T)	2	Torrance \| California \| United States \| -118.34063 \| 33.83585 Québec \| Quebec \| Canada \| -71.21454 \| 46.81228	80	NCT00924612	1COMPLETED	2010-07-01	2009-07-01	Clarus Therapeutics, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	70	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.	There are approximately 1 million Hepatitis C (HCV) patients in the US who have failed to respond to, or cannot tolerate, interferon or interferon plus ribavirin therapy. Significant adverse effects of interferon therapy include bone marrow depression (with reduced white blood cell and platelet counts) and major psychi...	Hepatitis C	HCV interferon-naive	null	2	arm 1: Study drug plus ribavirin arm 2: Study drug plus placebo for ribavirin	[ 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks intervention 2: 5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks intervention 3: Capsules identical to ribavirin in appearance containing inactive ingredients	intervention 1: ribavirin intervention 2: CTS-1027 intervention 3: Placebo for ribavirin	21	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Diego \| California \| United States \| -117.16472 \| 32.71571 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Washington D.C...	70	NCT00925990	1COMPLETED	2010-07-01	2009-06-01	Conatus Pharmaceuticals Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	113	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	1FEMALE	false	The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.	null	Fibromyalgia		null	2	arm 1: None arm 2: None	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be m...	intervention 1: Saizen® intervention 2: Placebo and Saizen®	1	Barcelona \| N/A \| Spain \| 2.15899 \| 41.38879	113	NCT00933686	1COMPLETED	2010-07-01	2007-12-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	-0
[ 4 ]	301	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.	null	Nocturia		null	2	arm 1: SER120 arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: SER120 intervention 2: Placebo	intervention 1: SER120 intervention 2: Placebo	1	Winston-Salem \| North Carolina \| United States \| -80.24422 \| 36.09986	301	NCT00937859	1COMPLETED	2010-07-01	2009-06-01	Serenity Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	12	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	No medication has been reliably shown to benefit those suffering from trichotillomania (compulsive hair pulling). The current study proposes to evaluate the effectiveness of the medication aripiprazole for treatment of trichotillomania (TTM). Patients will take a gradually increased dose of the medication in an open-la...	The proposed study is an 8-week, open-label trial of aripiprazole. The study would enroll 10 patients diagnosed with TTM meeting DSM-IV criteria. Subjects would start at a dose of 5 mg, which can be reduced to 2 mg if initial dose is not tolerated. Dose will be increased by 5 mg every two weeks (or as tolerated, with a...	Trichotillomania	trichotillomania aripiprazole treatment	null	1	arm 1: Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a low...	[ 0 ]	1	[ 0 ]	intervention 1: aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement...	intervention 1: aripiprazole	1	Stanford \| California \| United States \| -122.16608 \| 37.42411	11	NCT00947154	1COMPLETED	2010-07-01	2009-07-01	Stanford University	7OTHER	false	false	false	null	0
[ 0 ]	120	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	true	1FEMALE	false	Facial skin aging is a complex process combining factors such as sun exposure, smoking and those that are believed to be inherited. Changes in the skin over time including decreased thickness result in skin atrophy, wrinkling, sagging, yellowness and changes in pigmentation. Redermic is a cosmetic cream that has been e...	Facial skin aging is a complex and multifactorial process combining extrinsic and intrinsic factors. Major extrinsic factors include sun exposure and smoking while intrinsic factors are believed to be genetically programmed. Changes in the dermis are responsible for many of the important clinical changes associated wi...	Skin Aging	Skin Aging Rejuva-a Redermic	null	3	arm 1: Cream was applied twice a day every day, morning and evening for 24 weeks. arm 2: Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 \& 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every...	[ 0, 1, 1 ]	2	[ 10, 0 ]	intervention 1: Cosmetic cream formulation 609637 43. intervention 2: Tretinoin 0.025% cream.	intervention 1: Redermic intervention 2: Tretinoin (Rejuva-A)	1	Montreal \| Quebec \| Canada \| -73.58781 \| 45.50884	120	NCT00974480	1COMPLETED	2010-07-01	2009-09-01	Cosmetique Active International	4INDUSTRY	false	false	false	null	0
[ 5 ]	366	RANDOMIZED	PARALLEL	9OTHER	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.	Dyspnea, referred to by patients as "shortness of breath" or "breathlessness," is frequently associated with decreases in functional status, quality of life, and disabilities. Currently available questionnaires do not specifically address the shortness of breath component of COPD. The development of a patient reported ...	Pulmonary Disease, Chronic Obstructive	Pulmonary Disease, Chronic Obstructive Dyspnea	null	3	arm 1: Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day arm 2: Salmeterol 50mcg DISKUS twice a day arm 3: Placebo DISKUS twice a day	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks intervention 2: Salmeterol 50mcg DISKUS twice a day for 8 weeks intervention 3: Placebo DISKUS twice a day for 8 weeks	intervention 1: Fluticasone propionate/salmeterol combination product intervention 2: Salmeterol intervention 3: Placebo	39	Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Riverside \| California \| United States \| -117.39616 \| 33.95335 Wheat Ridge \| Colorado \| United States \| -105.07721 \| 39.7661 Stamford \| Connect...	365	NCT00984659	1COMPLETED	2010-07-01	2009-10-29	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 0 ]	70	NON_RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	Based on available mechanistic and clinical information, the investigators propose a nonrandomized study to evaluate the effect of succinylcholine in patients taking statins. The investigators' purpose is to evaluate the effect of succinylcholine on patients taking statins. Patients scheduled to undergo elective surger...	null	Pain	Succinylcholine Statins myalgias statins with succinylcholine and pain	null	2	arm 1: Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months. arm 2: Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.	[ 5, 5 ]	1	[ 0 ]	intervention 1: Succinylcholine will be administered pre-induction over a period of 5 seconds	intervention 1: Succinylcholine	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	70	NCT00986583	1COMPLETED	2010-07-01	2009-09-01	The Cleveland Clinic	7OTHER	false	false	false	null	0
[ 3 ]	66	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	1. The primary objective of this study is: * To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma 2. The se...	null	Exercise Induced Asthma	Exercise induced asthma Mild intermittent asthma Exercise induced bronchoconstriction	null	3	arm 1: budesonide 400yg + terbutaline 0.4 mg as-needed arm 2: placebo + terbutaline 0.4 mg as-needed arm 3: placebo + budesonide/formoterol 160/4.5 yg as-needed	[ 1, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 400 yg x 1 intervention 2: 0.4 mg as-needed intervention 3: 160/4.5 yg as-needed	intervention 1: budesonide intervention 2: terbutaline intervention 3: budesonide/formoterol	10	Oslo \| N/A \| Norway \| 10.74609 \| 59.91273 Trondheim \| N/A \| Norway \| 10.39506 \| 63.43049 Gothenburg \| N/A \| Sweden \| 11.96679 \| 57.70716 Huddinge \| N/A \| Sweden \| 17.98192 \| 59.23705 Linköping \| N/A \| Sweden \| 15.62157 \| 58.41086 Luleå \| N/A \| Sweden \| 22.15465 \| 65.58415 Lund \| N/A \| Sweden \| 13.19321 \| 55.70584 Skene...	66	NCT00989833	1COMPLETED	2010-07-01	2009-09-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 3 ]	115	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	1FEMALE	false	The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 days with a long term follow ...	null	Postoperative Pain	Postoperative pain Local anaesthesia Postoperative pain after open abdominal hysterectomy surgery	null	6	arm 1: double-blind arm 2: double-blind arm 3: double-blind arm 4: double-blind arm 5: double-blind arm 6: double-blind	[ 0, 2, 1, 0, 2, 1 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: 5.0 ml intervention 2: 5.0 ml intervention 3: 40 ml intervention 4: 7.5 ml intervention 5: 7.5 ml intervention 6: 40 ml	intervention 1: SABER-Bupivacaine Treatment 1a intervention 2: Placebo SABER-Bupivacaine Treatment 1b intervention 3: Bupivacaine HCl Treatment 1c intervention 4: SABER-Bupivacaine Treatment 2a intervention 5: Placebo SABER-Bupivacaine Treatment 2b intervention 6: Bupivacaine HCl Treatment 2c	14	Paris \| N/A \| France \| 2.3488 \| 48.85341 Bayreuth \| N/A \| Germany \| 11.57893 \| 49.94782 Dresden \| N/A \| Germany \| 13.73832 \| 51.05089 Békéscsaba \| N/A \| Hungary \| 21.1 \| 46.68333 Budapest \| N/A \| Hungary \| 19.04045 \| 47.49835 Debrecen \| N/A \| Hungary \| 21.62444 \| 47.53167 Győr \| N/A \| Hungary \| 17.63512 \| 47.68333 Nyír...	114	NCT00993226	1COMPLETED	2010-07-01	2009-05-01	Durect	4INDUSTRY	false	false	false	null	0
[ 4 ]	118	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.	null	Behcet Disease	Behçet's disease, intermediate uveitis panuveitis posterior uveitis uveitis	null	3	arm 1: AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks arm 2: AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e arm 3: Placebo was administered in 2 s.c. injections every 2 weeks	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None	intervention 1: AIN457 intervention 2: AIN457 intervention 3: Placebo	49	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Arlington \| Texas \| United States \| -97.10807 \| 32.73569 Houston \| Texas \| United States \| -95.36327 \| 29.76328 Alexandria \| N/A \| Egypt \| 29.91582 \| 31.20176 Grenoble \| N/A \| France \| 5.71479 \| 45.17869 Dessau \| N/A \| Germany \| 12.24555 \| 51.83864 Essen \| N/A...	117	NCT00995709	1COMPLETED	2010-07-01	2009-10-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 3 ]	78	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to help answer the following questions: * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control blood sugar in partic...	null	Diabetes Mellitus, Type 2		null	5	arm 1: Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks. arm 2: Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks. arm 3: Participa...	[ 2, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Administered po BID, prior to morning and evening meals for 12 weeks. intervention 2: Administered po for 12 weeks	intervention 1: Placebo intervention 2: LY2599506	16	Topeka \| Kansas \| United States \| -95.67804 \| 39.04833 Toms River \| New Jersey \| United States \| -74.19792 \| 39.95373 Syracuse \| New York \| United States \| -76.14742 \| 43.04812 St Leonards \| New South Wales \| Australia \| 151.19836 \| -33.82344 Daw Park \| South Australia \| Australia \| 138.58407 \| -34.98975 Box Hill \| Vic...	78	NCT01024244	6TERMINATED	2010-07-01	2009-12-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3 ]	151	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT0001442 has on the amount ...	This was a phase 2 study to evaluate the efficacy of EGT0001442. The study included two segments: Segment 1 was a single center, open labeled, ascending dose study in 4 groups of 5 diabetic subjects per group who received 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days. The subjects were in c...	Diabetes Mellitus Type 2	Diabetes Mellitus Type 2	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days. Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigne...	intervention 1: EGT0001442 intervention 2: Placebo capsules to match EGT0001442	12	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 National City \| California \| United States \| -117.0992 \| 32.67811 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Reading \| Pennsylvania \| Un...	149	NCT01029704	1COMPLETED	2010-07-01	2009-12-01	Theracos	4INDUSTRY	false	true	false	null	0
[ 3 ]	22	RANDOMIZED	CROSSOVER	0TREATMENT	3TRIPLE	false	1FEMALE	false	The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence	null	Stress Urinary Incontinence	Phase 2 stress urinary incontinence Fesoterodine	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods	intervention 1: Fesoterodine	1	Glostrup Municipality \| N/A \| Denmark \| 12.40377 \| 55.6666	62	NCT01042236	1COMPLETED	2010-07-01	2009-01-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 0 ]	61	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	The study is designed to assess methods used in clinical research.	null	Pain	Pilot Study to Assess Methodologies	null	4	arm 1: Heat device arm 2: Placebo arm arm 3: Marketed analgesic arm 4: (Oral) Placebo comparator	[ 1, 3, 1, 2 ]	4	[ 1, 1, 0, 0 ]	intervention 1: 8-Hour Heatwrap intervention 2: Inactive wrap worn for 8 hours intervention 3: 2 x 200 mg ibuprofen tablets intervention 4: 2 x placebo tablets	intervention 1: Heat Device intervention 2: Sham Device intervention 3: marketed analgesic intervention 4: Placebo	1	Loma Linda \| California \| United States \| -117.26115 \| 34.04835	61	NCT01045993	1COMPLETED	2010-07-01	2010-02-01	Wyeth is now a wholly owned subsidiary of Pfizer	4INDUSTRY	false	false	false	null	0
[ 3, 4 ]	38	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	0ALL	true	The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure in the volume overload of mitral regurgitation (MR). Patients without coronary artery disease and moderate MR, as assessed by color/f...	In Western society, the most common causes of chronic mitral regurgitation (MR) are ischemic heart disease and myxomatous degeneration of the valve, resulting in prolapse, ruptured chordae or partial flail leaflet. Current indications for surgery are only for patients with severe MR and either notable symptoms or overt...	Mitral Regurgitation	Chronic MR Volume Overload Beta-1 receptor blocker LV remodelling, LV dimensions LV systolic function LV diastolic dysfunction Cardiac MRI	null	2	arm 1: beta 1 receptor blockade; generic name metoprolol succinate arm 2: Pill that looks like Toprol XL but does not have the active ingredients	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Toprol XL 100 mg once a day for 2 years intervention 2: Placebo 100 mg once a day for 2 years	intervention 1: metoprolol succinate (Toprol XL) intervention 2: Placebo	1	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066	38	NCT01052428	1COMPLETED	2010-07-01	2004-08-01	University of Alabama at Birmingham	7OTHER	false	false	false	null	0
[ 4 ]	80	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	Gabapentin is an antiepileptic drug. Its antiemetic effect is demonstrated after laparoscopic surgery, but it is not yet known whether gabapentin is effective in preventing chemotherapy induced emesis. The purpose of this study is to determine whether the addition of gabapentin to dexamethasone plus ondansetron increa...	This was a prospective, double-blind, placebo-controlled study conducted at our institution (Faculdade de Medicina da Fundação ABC and affiliated Hospitals) from April 2009 to April 2010. Patients and personnel involved in the study were blinded to the assigned treatment. The study was approved by the ethics committee ...	Vomiting Cisplatin Adverse Reaction	Vomiting Antiemetics Dexamethasone Cisplatin Antineoplastic combined chemotherapy protocols	null	2	arm 1: Placebo: * Five and four days before chemotherapy (day -5 and day -4): 1x daily * Three and two days before chemotherapy (day -3 and day -2): 2x daily * One day before to five days after chemotherapy ( day -1 to day 5): 3x daily arm 2: Gabapentin 300mg: * Five and four days before chemotherapy (day -5 and day ...	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3) intervention 2: Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 ...	intervention 1: Placebo intervention 2: Gabapentin	1	Santo André \| São Paulo \| Brazil \| -46.53833 \| -23.66389	80	NCT01052844	1COMPLETED	2010-07-01	2009-01-01	Faculdade de Medicina do ABC	7OTHER	false	false	false	null	0
[ 3 ]	104	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	null	This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence	null	Eyelash Hypotrichosis		null	3	arm 1: bimatoprost ophthalmic sterile solution 0.005% arm 2: bimatoprost ophthalmic sterile solution 0.015% arm 3: bimatoprost ophthalmic solution 0.03%	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin) intervention 2: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin) intervention 3: One drop...	intervention 1: bimatoprost ophthalmic solution 0.005% intervention 2: bimatoprost ophthalmic solution 0.015% intervention 3: bimatoprost ophthalmic solution 0.03%	1	San Diego \| California \| United States \| -117.16472 \| 32.71571	104	NCT01064882	1COMPLETED	2010-07-01	2010-03-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 4 ]	5	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.	This study was terminated on May 7, 2010 due to modification of the dimebon development plan, following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy ...	Alzheimer's Disease	Delirium Dementia Amnestic Cognitive Disorders Mental Disorders Nervous System Diseases Central Nervous System Diseases	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study	intervention 1: Dimebon tablet for oral administration	5	Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Encino \| California \| United States \| -118.50119 \| 34.15917 Los Alamitos \| California \| United States \| -118.07256 \| 33.80307 Newport Beach \| California \| United States \| -117.92895 \| 33.61891 Delray Beach \| Florida \| United States \| -80.07282 \| 26.46146	5	NCT01066546	6TERMINATED	2010-07-01	2010-04-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 4 ]	410	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.	null	Head Lice	Head lice Pediculus humanus capitis	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1 intervention 2: Up to 4 ounces of vehicle control applied to the hair and scalp on day 1	intervention 1: Ivermectin Cream intervention 2: vehicle control	8	Yuma \| Arizona \| United States \| -114.6244 \| 32.72532 Dinuba \| California \| United States \| -119.38707 \| 36.54328 Plantation \| Florida \| United States \| -80.23184 \| 26.13421 West Palm \| Florida \| United States \| N/A \| N/A Picayune \| Mississippi \| United States \| -89.67788 \| 30.52556 Miamiville \| Ohio \| United States \| ...	409	NCT01066585	1COMPLETED	2010-07-01	2010-03-01	Topaz Pharmaceuticals Inc	4INDUSTRY	false	false	false	null	0
[ 4 ]	371	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.	null	Head Lice	Head lice infestation Pediculus humanus capitis	null	2	arm 1: Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1 arm 2: Up to 4 ounces of topical control applied to hair and scalp on day 1.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1. intervention 2: up to 4 ounces of topical vehicle control to head and scalp on day 1.	intervention 1: 0.5% Ivermectin Cream intervention 2: Placebo control	7	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Delray Beach \| Florida \| United States \| -80.07282 \| 26.46146 St. Petersburg \| Florida \| United States \| -82.67927 \| 27.77086 Albuquerque \| New Mexico \| United States \| -106.65114 \| 35.08449 Clyde \| North Carolina \| United States \| -82.91069 \| 35.53344 Nashv...	371	NCT01068158	1COMPLETED	2010-07-01	2010-03-01	Topaz Pharmaceuticals Inc	4INDUSTRY	false	false	false	null	0
[ 4 ]	54	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in subjects with Chronic Obstructive Pulmonary Disease (COPD) compared with placebo. Other object...	null	Pulmonary Disease, Chronic Obstructive	COPD Safety FEV1 Efficacy	null	4	arm 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 2: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 3: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 4: placebo	[ 0, 0, 0, 2 ]	2	[ 0, 1 ]	intervention 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD intervention 2: placebo	intervention 1: Fluticasone Furoate (FF)/GW642444 Inhalation Powder intervention 2: placebo	8	DeLand \| Florida \| United States \| -81.30312 \| 29.02832 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Madisonville \| Kentucky \| United States \| -87.49889 \| 37.3281 Columbus \| Ohio \| United States \| -82.99879 \| 39.96118 Greenville \| South Carolina \| United States \| -82.39401 \| 34.85262 Orangeburg \| South Caro...	149	NCT01072149	1COMPLETED	2010-07-01	2010-01-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 4 ]	323	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.	null	Chronic Obstructive Pulmonary Disease	COPD indacaterol	null	2	arm 1: Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. intervention 2: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.	intervention 1: Indacaterol 75 μg intervention 2: Placebo to indacaterol	62	Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Pine Bluff \| Arkansas \| United States \| -92.0032 \| 34.22843 Buena Park \| California \| United States \| -117.99812 \| 33.86751 Encinitas \| California \| United States \| -117.29198 \| 33.03699 Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Los Ange...	323	NCT01072448	1COMPLETED	2010-07-01	2010-01-01	Novartis	4INDUSTRY	false	false	false	null	0
[ 0 ]	4	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).	null	Autism Asperger's Disorder Pervasive Developmental Disorder NOS	Autism Asperger's Disorder Pervasive Developmental Disorder NOS Adult Memantine	null	2	arm 1: Treatment as usual plus placebo arm 2: Treatment as usual plus memantine	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: memantine 5-20 mg daily intervention 2: Look-alike placebo	intervention 1: memantine intervention 2: Placebo	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	4	NCT01078844	6TERMINATED	2010-07-01	2010-02-01	Johns Hopkins University	7OTHER	false	false	false	null	0
[ 4 ]	511	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol	null	Asthma	Indacaterol asthma salmeterol	null	6	arm 1: Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable througho...	[ 0, 0, 0, 0, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme. intervention 2: 50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks. intervention 3: Placebo to Indacaterol once daily in the morni...	intervention 1: Indacaterol intervention 2: Salmeterol intervention 3: Placebo to Indacaterol intervention 4: Placebo to Salmeterol	71	Glendale \| Arizona \| United States \| -112.18599 \| 33.53865 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Encinitas \| California \| United States \| -117.29198 \| 33.03699 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los...	502	NCT01079130	1COMPLETED	2010-07-01	2010-02-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	552	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.	null	Chronic Obstructive Pulmonary Disease	Indacaterol COPD salmeterol	null	6	arm 1: Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks...	[ 0, 0, 0, 0, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. intervention 2: Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device. intervention 3: Placebo to indacaterol was supplied in powder filled capsules together with a...	intervention 1: Indacaterol intervention 2: Salmeterol 50 μg intervention 3: Placebo to indacaterol intervention 4: Placebo to salmeterol	69	Florence \| Alabama \| United States \| -87.67725 \| 34.79981 Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Searcy \| Arkansas \| United States \| -91.73625 \| 35.25064 Fullerton \| California \| United States \| -117.92534 \| 33.87029 Rancho Mirage \| California \|...	547	NCT01089127	1COMPLETED	2010-07-01	2010-03-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 0 ]	19	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to study the tolerances of Extremely Low Birthweight Infants who are born at less than 750 grams who are started at a higher infusion rate of intravenous lipid emulsions (2 gm/kg/day). These infants will be compared with a control group who are at the standard lipid emulsion infusion rate (...	ELBW infants will be randomized into either the control group or the experimental group. The control group will receive standardized care which consists of receiving TPN within 24 to 36 hours of life. The control group will be given the standardized dosage of IVFE starting at 0.5 grams/kg/day in the TPN and have IVFE ...	Hypertriglyceridemia Hyperglycemia		null	2	arm 1: Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN. arm 2: Infants randomized into the control ...	[ 0, 5 ]	1	[ 0 ]	intervention 1: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day	intervention 1: Intravenous Fat Emulsions	1	Peoria \| Illinois \| United States \| -89.58899 \| 40.69365	19	NCT01096446	6TERMINATED	2010-07-01	2008-04-01	OSF Healthcare System	7OTHER	false	false	false	null	0
[ 5 ]	100	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	At present, there is some clinical data for different functional response to beta-blockers associated with beta-adrenergic receptor polymorphisms. But there has been no data reported, about the incidence of beta-adrenergic receptor polymorphism and association with beta-adrenergic receptor polymorphism and response to ...	Heart failure impairs the quality of life of an individual and is considered to be the main cause of morbidity and mortality. Prognosis of HF subjects depends on severity, age and sex. Subjects with HF require lifelong treatment. Pharmacological treatment aims to improve both the quality of life and survival of HF subj...	Chronic Heart Failure	Bisoprolol Chronic Heart failure	null	0	null	null	1	[ 0 ]	intervention 1: Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased a...	intervention 1: Bisoprolol	1	Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	100	NCT01104558	1COMPLETED	2010-07-01	2008-12-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0
[ 2 ]	18	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	2MALE	null	The objective of the current study is to investigate the bioavailability of BI 10773 and of warfarin after concomitant multiple oral administration of BI 10773 and a single oral dose of warfarin in comparison to BI 10773 and warfarin given alone, and to investigate the pharmacodynamics of a single oral dose of warfarin...	null	Healthy		null	3	arm 1: 1 tablet 25 mg BI 10773 qd for 5 days arm 2: 1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose arm 3: 5 tablets 5 mg warfarin single dose	[ 0, 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 25 mg BI 10773 qd for 5 days intervention 2: 25 mg Warfarin single dose intervention 3: 25 mg BI 10773 qd for 12 days intervention 4: 25 mg warfarin single dose with and without 50 mg BI 10773	intervention 1: BI 10773 25 mg intervention 2: Warfarin 25 mg intervention 3: BI 10773 25 mg intervention 4: Warfarin	1	Biberach \| N/A \| Germany \| 8.03333 \| 48.33333	54	NCT01111331	1COMPLETED	2010-07-01	2010-05-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 3 ]	83	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.	null	Allergic Conjunctivitis		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 1, 1, 5 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 1 drop in each eye for up to 14 days intervention 2: 1 drop in each eye once per day for up to 14 days intervention 3: 1 drop in each eye once per day for up to 14 days intervention 4: 1 drop in each eye once per day for up to 14 days	intervention 1: AC-150 Combo intervention 2: AC-150A 0.1% intervention 3: AC-150B 0.005% intervention 4: Vehicle	1	Andover \| Massachusetts \| United States \| -71.137 \| 42.65843	83	NCT01134328	1COMPLETED	2010-07-01	2010-05-01	Aciex Therapeutics, Inc.	4INDUSTRY	false	false	false	null	0
[ 2 ]	16	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	0NONE	true	2MALE	false	The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.	null	Healthy	pharmacokinetic eletriptan Korean crossover	null	4	arm 1: 1 X 20 mg eletriptan arm 2: 1 X 40 mg eletriptan arm 3: 2 X 40 mg eletriptan arm 4: 1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 20 mg tablet, single dose intervention 2: 40 mg tablet, single dose of 1 X 40 mg intervention 3: 40 mg tablet, single dose of 2 X 40 mg intervention 4: 40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first	intervention 1: Eletriptan commercial tablet intervention 2: Eletriptan commercial tablet intervention 3: Eletriptan commercial tablet intervention 4: Eletriptan commercial tablet	1	Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	64	NCT01139515	1COMPLETED	2010-07-01	2010-07-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle scarring.	Hypertrophic cardiomyopathy (HCM) is characterized by idiopathic cardiac hypertrophy, heart failure, ischemia even in the absence of epicardial coronary artery disease, and arrhythmias. The pathological features of HCM include hypertrophy and disarray, interstitial fibrosis, and increased arteriolar wall thickness. Hyp...	Hypertrophic Cardiomyopathy	Hypertrophic nonobstructive cardiomyopathy	null	2	arm 1: Losartan 50 mg b.i.d. arm 2: Placebo b.i.d.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Losartan 50 mg b.i.d intervention 2: Placebo b.i.d.	intervention 1: losartan intervention 2: placebo	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	20	NCT01150461	1COMPLETED	2010-07-01	2007-02-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0
[ 2 ]	26	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	This study will research the existance of actual bioequivalence between Diltiazem in 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. DE C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. DE C.V.	Bioequivalence of this particular drug	Healthy	diltiazem angiotrofin bioequivalence	null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/sh...	intervention 1: TILACEM intervention 2: ANGIOTROFIN	1	Mexico City \| Mexico City \| Mexico \| -99.12766 \| 19.42847	50	NCT01151345	1COMPLETED	2010-07-01	2010-06-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 2 ]	35	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	null	This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol	null	Healthy Pulmonary Disease, Chronic Obstructive		null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 10 mcg solution for oral inhalation intervention 2: 400 mg capsule	intervention 1: BI 1744 intervention 2: Fluconazole	1	Berlin \| N/A \| Germany \| 13.41053 \| 52.52437	69	NCT01153724	1COMPLETED	2010-07-01	2010-05-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 3 ]	191	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	This study assessed the bronchodilator efficacy of three different regimens of indacaterol in patients with asthma	null	Persistent Asthma	Indacaterol Asthma Bronchodilation Beta-agonist	null	4	arm 1: Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening ...	[ 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme. intervention 2: Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.	intervention 1: Indacaterol intervention 2: Placebo to Indacaterol	30	Anniston \| Alabama \| United States \| -85.83163 \| 33.65983 Cypress \| California \| United States \| -118.03729 \| 33.81696 Fresno \| California \| United States \| -119.77237 \| 36.74773 San Diego \| California \| United States \| -117.16472 \| 32.71571 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Clearwater \| Florida ...	189	NCT01156844	1COMPLETED	2010-07-01	2010-03-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 3 ]	50	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally advanced or metastatic colorectal cancer. The a...	null	Colorectal Cancer		null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: 5 mg/kg intravenously every 14 days intervention 2: 1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle intervention 3: 40 mg/m2 iv weekly	intervention 1: bevacizumab [Avastin] intervention 2: capecitabine [Xeloda] intervention 3: oxaliplatin	6	Aviano \| N/A \| Italy \| 12.59472 \| 46.07056 Fano \| N/A \| Italy \| 13.01665 \| 43.84052 Palermo \| N/A \| Italy \| 13.3636 \| 38.1166 Rimini \| N/A \| Italy \| 12.56528 \| 44.05755 Roma \| N/A \| Italy \| 11.10642 \| 44.99364 Torino \| N/A \| Italy \| 11.99138 \| 44.88856	49	NCT01159171	1COMPLETED	2010-07-01	2006-01-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 5 ]	79	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.	This study is planned to evaluate emotional disorders during treatment by IFN beta in RRMS subjects. This is an open-label, prospective, interventional, multicentric study with no change of therapeutic behavior but with standardized neuropsychologic follow-up. Subjects will undergo 13 evaluations (categorical and dimen...	Multiple Sclerosis, Relapsing, Remitting	Multiple sclerosis, relapsing, remitting Interferon-beta	null	0	null	null	1	[ 0 ]	intervention 1: None	intervention 1: Interferon beta-1a	0	null	76	NCT01201343	1COMPLETED	2010-07-01	2005-01-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0
[ 5 ]	1,179	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	false	The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo	null	Acute Upper Respiratory Track Infection	Acute Upper Respiratory Track Infection Who Seek Treatment	null	2	arm 1: Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days arm 2: Placebo given bid with a full glass of water for 7 days	[ 1, 2 ]	2	[ 0, 1 ]	intervention 1: 1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days intervention 2: Placebo bid for 7 days	intervention 1: Guaifenesin intervention 2: Placebo	24	Mesa \| Arizona \| United States \| -111.82264 \| 33.42227 Carmichael \| California \| United States \| -121.32828 \| 38.61713 Fresno \| California \| United States \| -119.77237 \| 36.74773 San Luis Obispo \| California \| United States \| -120.65962 \| 35.28275 New London \| Connecticut \| United States \| -72.09952 \| 41.35565 Newark \|...	1,184	NCT01202279	1COMPLETED	2010-07-01	2009-10-01	Reckitt Benckiser Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	10	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone.	The study was designed such that 30 participants would be consented/enrolled into the trial. The intervention would only be applied if the participant developed a viral illness that met eligibility criteria during the study period. Only 10 of the 30 ppt. consented/enrolled developed a virus and were then treated accor...	Asthma	Asthma	null	2	arm 1: Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions. Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either ...	[ 1, 2 ]	1	[ 0 ]	intervention 1: None	intervention 1: Symbicort	1	Stanford \| California \| United States \| -122.16608 \| 37.42411	20	NCT01218399	1COMPLETED	2010-07-01	2009-09-01	Stanford University	7OTHER	false	false	false	null	0
[ 3 ]	1	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The goal of this clinical research study is to learn if lenalidomide and darbepoetin alfa given together will help to control the need for transfusions in patients with low to intermediate risk Myelodysplastic Syndrome (MDS). The safety of this combination will also be studied.	Lenalidomide is designed to change the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may decrease or prevent the growth of cancer cells. Darbepoetin alfa is designed to stimulate production of red blood cells. If you are foun...	Leukemia	Myelodysplastic Syndrome Red cell transfusion independence Darbepoetin alfa Lenalidomide CC-5013 Revlimid Aranesp Erythropoietin Erythropoiesis Stimulating Protein	null	1	arm 1: Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle	[ 0 ]	2	[ 0, 0 ]	intervention 1: 10 mg/day by mouth on days 1-21 of every 28 day cycle. intervention 2: 200 mcg subcutaneously every 2 weeks of a 28 cycle.	intervention 1: Lenalidomide intervention 2: Darbepoetin alfa	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	1	NCT01222195	6TERMINATED	2010-07-01	2008-02-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0
[ 4 ]	365	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	The objective of this study is to compare the efficacy and safety of Fluticasone Furoate Nasal Spray (FFNS), that is FFNS with placebo in Chinese adult and adolescent subjects with Allergic Rhinitis as AR. There are 3 phases, 2 to14 day run in, 2 week treatment, and 3 to 5 day follow up. After run in period, at least 3...	This is a multicenter, 2 week, double blind, randomized, placebo controlled trial. 7 investigational sites will be enlisted to randomize at least 360 subjects (outpatients) during 2009 and 2010. Throughout the entire study period, no antiallergy drugs and rhinitis medication, including rescue medication for symptom rel...	Rhinitis, Allergic, Perennial Allergic Rhinitis	safety efficacy placebo allergic rhinitis fluticasone furoate	null	2	arm 1: vehicle placebo nasal spray arm 2: fluticasone furoate nasal spray	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: fluticasone furoate nasal spray 110ug, once daily intervention 2: placebo	intervention 1: fluticasone furoate nasal spray intervention 2: placebo	7	Nanjing \| Jiangsu \| China \| 118.77778 \| 32.06167 Chengdu \| Sichuan \| China \| 104.06667 \| 30.66667 Hangzhou \| Zhejiang \| China \| 120.16142 \| 30.29365 Beijing \| N/A \| China \| 116.39723 \| 39.9075 Shanghai \| N/A \| China \| 121.45806 \| 31.22222 Shanghai \| N/A \| China \| 121.45806 \| 31.22222 Wuhan \| N/A \| China \| 114.26667 \| 3...	363	NCT01231464	1COMPLETED	2010-07-01	2009-09-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 5 ]	43	NON_RANDOMIZED	PARALLEL	9OTHER	0NONE	true	0ALL	true	This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection. Additionally, markers of side effects were correlated with blood levels of the drugs. The hypothesis was that women and those with HIV would have higher drug leve...	null	HIV	Pharmacokinetics antiretroviral therapy nucleoside analogs mitochondrial toxicity clinical pharmacology cellular pharmacology pharmacogenetics	null	2	arm 1: This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women. arm 2: This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.	[ 1, 1 ]	1	[ 0 ]	intervention 1: twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group	intervention 1: zidovudine 300mg and lamivudine 150mg as Combivir	1	Aurora \| Colorado \| United States \| -104.83192 \| 39.72943	43	NCT01386970	1COMPLETED	2010-07-01	2005-05-01	University of Colorado, Denver	7OTHER	false	false	false	null	0
[ 4 ]	232	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.	Open label Extension Phase: The 130-week Extension Phase was conducted to provide information regarding long-term safety and efficacy of aripiprazole in participants who were diagnosed at the onset of the Acute Phase with psychotic symptoms associated with dementia of the Alzheimer's type who responded to treatment in ...	Dementia, Alzheimer Type		null	2	arm 1: Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140) arm 2: Double blind Acute Phase (Week 1 to Week 10)	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks interve...	intervention 1: Aripiprazole (BMS-337039) intervention 2: Placebo	0	null	368	NCT01438060	1COMPLETED	2010-07-01	2000-08-01	Otsuka Pharmaceutical Development & Commercialization, Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	608	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who complet...	null	Macular Edema Retinal Vein Occlusion	CNV Lucentis AMD Age-related macular degeneration RVO Macular edema secondary to retinal vein occlusion	null	1	arm 1: Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.	[ 0 ]	1	[ 0 ]	intervention 1: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).	intervention 1: Ranibizumab 0.5 mg	0	null	602	NCT01442064	1COMPLETED	2010-07-01	2008-07-01	Genentech, Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	54	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	2MALE	true	The purpose of the proposed study is to determine if pairing reactivation of a traumatic memory with a single administration of Rapamycin (e.g., Sirolimus) in men with combat-related Posttraumatic Stress Disorder leads to a reduction of the emotional strength of that particular traumatic memory. The following hypothes...	Post-traumatic stress disorder (PTSD) is characterized by intrusive memories in the form of unwanted images, nightmares, and flashbacks as the result of being exposed to a traumatic event . Current research efforts have begun to explore the underlying neurochemical changes associated with PTSD. Recently, these efforts ...	Posttraumatic Stress Disorder	PTSD	null	2	arm 1: 15 mg Placebo will be administered once, in pill form. arm 2: 15 mg of Rapamycin will be administered once, in pill form.	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotio...	intervention 1: Rapamycin intervention 2: Placebo	1	Dallas \| Texas \| United States \| -96.80667 \| 32.78306	54	NCT01449955	1COMPLETED	2010-07-01	2008-08-01	University of Texas Southwestern Medical Center	7OTHER	false	false	false	null	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.